enGene Therapeutics, Inc. (ENGN), a clinical-stage biotechnology company, reported results for the second quarter that ended on April 30, 2026, reflecting a wider net loss compared to the prior year and provided an update on near-term clinical and regulatory milestones.
Company Profile
enGene Therapeutics focuses on developing non-viral genetic medicines for patients with bladder cancer, particularly non-muscle-invasive bladder cancer (NMIBC).
The company's lead investigational asset, Detalimogene voraplasmid (previously known as EG-70), is a gene therapy currently being evaluated in the Phase 2 LEGEND trial for patients with NMBIC, including those with Bacillus Calmette-Guérin (BCG)-unresponsive disease.
The therapy has received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations from the U.S. Food and Drug Administration (FDA) for patients with BCG-unresponsive carcinoma in situ (CIS) NMIBC.
Second Quarter 2026 Financial Results
enGene's net loss for the three months ended April 30, 2026, totalled $30.23 million, or $0.43 per share, from a net loss of $25.82 million, or $0.51 per share. The company attributed the wider loss primarily to increased operating expenses, partially offset by net interest income earned during the quarter.
As of the quarter ended on April 30, 2026, cash, cash equivalents, and marketable securities totalled $285.17 million.
Milestones Ahead
- enGene expects to report 12-month complete response data from Phase 2 LEGEND's pivotal Cohort 1 that evaluates Detalimogene.
- First patient enrolled in the detalimogene plus surfactant cohort.
-Based on the results, the company expects to subsequently engage with the FDA to discuss a pre-Biologics License Application (BLA) filing in the second half of 2026.
enGene Therapeutics shares closed Monday at $1.77, up 9.26%. In the overnight market, the shares are trading at $1.79, up 1.13%.
For more such biotech stock news, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.